Evgen Pharma plc (EVG.L) – BUY*: Clinical trial approval | Motif Bio plc (MTFB.L) – BUY*: Commencement of Phase 3 trials | Botswana Diamonds (BOD.L) – SPECULATIVE BUY*: Exploration update | Global Energy Developments (GED.L) – CORP: FY15 results | Keras Resources (KRS.L) – CORP: Grants Patch update | Churchill Mining (CHL.L) – SPECULATIVE BUY*: Company update | DiamondCorp (DCP.L): Resource Statement
02 Mar 2016
Northland Capital Morning Report
Sign up to access
Get access to our full offering from over 100 providers
Get access to our full offering from over 100 providers
Northland Capital Morning Report
TheraCryf PLC (TCF:LON), 0.2 | Botswana Diamonds Plc (BOD:LON), 0.3 | Nautilus Marine Services (NAUT:LON), 0 | Keras Resources Plc (KRS:LON), 1.4 | Diamondcorp (DCP:LON), 0 | Cloudified Holdings Limited (CHL:LON), 2.2
- Published:
02 Mar 2016 -
Author:
Vadim Alexandre -
Pages:
7 -
Evgen Pharma plc (EVG.L) – BUY*: Clinical trial approval | Motif Bio plc (MTFB.L) – BUY*: Commencement of Phase 3 trials | Botswana Diamonds (BOD.L) – SPECULATIVE BUY*: Exploration update | Global Energy Developments (GED.L) – CORP: FY15 results | Keras Resources (KRS.L) – CORP: Grants Patch update | Churchill Mining (CHL.L) – SPECULATIVE BUY*: Company update | DiamondCorp (DCP.L): Resource Statement